Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PTC Therapeutics (PTCT)

PTC Therapeutics Q1 net income of $866.6 million on one-time $986.2 million license revenue

Mixed Impact 4 of 5 earnings Written later

PTC Therapeutics reported first quarter 2025 results, with total revenue of $1,176.1 million and net income of $866.6 million, compared with a net loss of $91.6 million a year earlier. The results were driven by a $986.2 million license and collaboration payment from Novartis for PTC518, while net product and royalty revenue fell to $189.9 million from $208.8 million. The company narrowed its full-year 2025 revenue guidance to $650 million to $800 million.

Key points

  • Total revenue was $1,176.1 million, versus $210.1 million in the first quarter of 2024, including $986.2 million tied to the PTC518 license with Novartis, which closed in January 2025.
  • Net product and royalty revenue was $189.9 million, down from $208.8 million a year earlier.
  • Net income was $866.6 million, or $10.04 per diluted share, compared with a net loss of $91.6 million, or $1.20 per share, in the first quarter of 2024.
  • Full-year 2025 revenue guidance was narrowed to $650 million to $800 million; cash and marketable securities were $2,027.2 million as of March 31, 2025.

The filing

CompanyPTC Therapeutics (PTCT)
Form8-K, current report
Filed with the SECMay 6, 2025, 4:03 PM ET
Accession number0001070081-25-000018

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.